Endoscopic ultrasound-guided ablation of pancreatic cystic neoplasms: ready for prime time?

Ofosu, Andrew; Ramai, Daryl; Adler, Douglas G.

doi:10.20524/aog.2018.0331

Cited by 5 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 47 ] Due to its viscous, hydrophobic nature, it is theorized to be less likely to extravasate out of the cyst and allow for increased duration of contact with the epithelial lining. [ 17 47 48 49 ] Studies examining EUS-guided paclitaxel ablation have been summarized in Table 2 .…”

Section: Eus-guided Paclitaxel Ablationmentioning

confidence: 99%

See 1 more Smart Citation

An update on EUS-guided ablative techniques for pancreatic cystic lesions

Ardeshna¹,

Woods²,

Tsung³

et al. 2022

Endosc Ultrasound

View full text Add to dashboard Cite

Pancreatic cystic lesions (PCLs) are increasingly being recognized due to improvements and widespread use of cross-sectional imaging. With an estimated prevalence of 15% in general population, incidentally discovered PCLs represent a dilemma in management. While pancreatectomies offer a chance of cure, the morbidity is considerable in patients with high surgical risks. More recently, EUS-guided approaches for cyst ablation are being offered in clinical trials for the management of PCLs. EUS-chemoablation studies have progressed from first investigating safety and efficacy of EUS-guided alcohol lavage to single-agent paclitaxel ablation. Recent studies have shown that alcohol lavage may not be required, and long-term resolution can be achieved by chemoablation alone. EUS-guided lauromacrogol ablation and EUS-guided radiofrequency ablation (RFA) are new techniques that have shown promising results in a few small studies. Overall, the current literature suggests that EUS-guided paclitaxel ablation has better cyst resolution rates compared to other existing minimally invasive techniques including ethanol injection, lauromacrogol ablation, or RFA. This article will review EUS-guided PCL ablation approaches and future directions the field is headed into.

show abstract

Section: Eus-guided Paclitaxel Ablationmentioning

confidence: 99%

“…[ 16 ] In addition, the lack of evidence on long-term mortality benefits for surveillance techniques further contends this option. [ 1 16 17 ]…”

Section: Introductionmentioning

confidence: 99%

An update on EUS-guided ablative techniques for pancreatic cystic lesions

Ardeshna¹,

Woods²,

Tsung³

et al. 2022

Endosc Ultrasound

View full text Add to dashboard Cite

show abstract

“…By contrast, potential adverse events may arise as a result of the effect of thermal injury, which can lead to biliary leakage and pancreatic and vascular injury[ 78 ]. Nevertheless, the data of PCNs’ EUS-RFA are limited to a few human case series and animal data, and an ongoing Phase II multicenter trial of EUS-RFA has been conducted to evaluate the outcomes of the pancreatic cyst at 12 mo following cyst RFA[ 93 ].…”

Section: Eus-rfamentioning

confidence: 99%

Cystic pancreatic lesions, the endless dilemma

Okasha¹,

Awad²,

Elmeligui³

et al. 2021

WJG

View full text Add to dashboard Cite

Cystic pancreatic lesions involve a wide variety of pathological entities that include neoplastic and non-neoplastic lesions. The proper diagnosis, differentiation, and staging of these cystic lesions are considered a crucial issue in planning further management. There are great challenges for their diagnostic models. In our time, new emerging methods for this diagnosis have been discovered. Endoscopic ultrasonography-guided fine-needle aspiration cytology with chemical and molecular analysis of cyst fluid and EUS-guided fine needle-based confocal laser endomicroscopy, through the needle microforceps biopsy, and single-operator cholangioscopy/pancreatoscopy are promising methods that have been used in the diagnosis of cystic pancreatic lesions. Hereby we discuss the diagnosis of cystic pancreatic lesions and the benefits of various diagnostic models.

show abstract

“…RFA has been employed to manage a variety of GI lesions endoscopically. RFA has been shown to be a promising approach in treating cystic pancreatic neoplasms and Barrett’s esophagus [23,24]. Little is known about the clinical and technical success of RFA in managing GI tumor related bleeding.…”

Section: Radiofrequency Ablation (Rfa)mentioning

confidence: 99%

Endoscopic management of bleeding gastrointestinal tumors

Ofosu

Ramai

Latson

et al. 2019

aog

Self Cite

View full text Add to dashboard Cite

Bleeding due to primary or metastatic gastrointestinal (GI) tumors remains clinically challenging. Bleeding is further complicated in the setting of underlying friable neovascularization of tumors and coagulopathy. Endoscopic hemostatic therapeutic options have traditionally involved the use of thermal/mechanical therapy in conjunction with injection therapy. This review looks at the role of endoscopy in managing tumor-related GI bleeding, specifically contact and non-contact thermal therapy, radiofrequency ablation, endoloops, epinephrine and ethanol injection, and, most recently, Hemospray. Overall, current data show that endoscopic therapy is limited, with high rebleeding rates and a failure to improve overall outcomes. Larger clinical trials are needed to determine the efficacy of current techniques and establish therapeutic algorithms, with the goal of achieving primary hemostasis and reducing rebleeding rates.

show abstract

Endoscopic ultrasound-guided ablation of pancreatic cystic neoplasms: ready for prime time?

Cited by 5 publications

References 44 publications

An update on EUS-guided ablative techniques for pancreatic cystic lesions

An update on EUS-guided ablative techniques for pancreatic cystic lesions

Cystic pancreatic lesions, the endless dilemma

Endoscopic management of bleeding gastrointestinal tumors

Contact Info

Product

Resources

About